Diagnostics for early detection of cancer. OncoMethylome develops diagnostic tests for the early detection of cancer. It specializes in the development of assays based on methylation-specific PCR (PCR) that detects abnormal DNA methylation pathways. It is currently developing tests for prostate, bladder, colorectal, breast and cervical cancers. Founded in 2003, headquartered in Antwerp, Belgium. The company operates in the Life Sciences > Genomics, Life Sciences > Oncology sector. Founded in 2003 and headquartered in Antwerp, Belgium and has raised $33.9 million in Series B funding. Key investors include PolyTechnos Venture Partners, Edmond de Rothschild, ING, Life Sciences Partners, Noshaq, EQT.
← All startups
OncoMethylome
Series BDiagnostics for early detection of cancer. OncoMethylome develops diagnostic tests for the early detection of cancer. It specializes in the development of assays based on methylation-specific PCR (PCR) that detects abnormal DNA methylation pathways. It is currently developing tests for prostate, bladder, colorectal, breast and cervical cancers. Founded in 2003, headquartered in Antwerp, Belgium. The company operates…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Pan Cancer,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Genetic Diagnosis > Epigenomics
Institutional investors
PolyTechnos Venture PartnersEdmond de RothschildINGLife Sciences PartnersNoshaqEQT
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Backed by funds in our directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.